Trade

Concord Biotech share price

High risk
  • 46%Low risk
  • 46%Moderate risk
  • 46%Balanced risk
  • 46%High risk
  • 46%Extreme risk
  • 1,271.55(6.18%)
    June 9, 2026 15:59:46 PM IST
    • NSE
    • BSE
  • Vol : 544.99 K (NSE + BSE)
    Last 20 day avg : 591.24 K

Concord Biotech is trading 6.18% upper at Rs 1,271.55 as compared to its last closing price. Concord Biotech has been trading in the price range of 1,281.00 & 1,192.35. Concord Biotech has given -11.07% in this year & 12.76% in the last 5 days. Concord Biotech has TTM P/E ratio 41.13 as compared to the sector P/E of 27.34.There are 4 analysts who have initiated coverage on Concord Biotech. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 88.79 Crores in its last quarter.Listed peers of Concord Biotech include Torrent Pharmaceuticals (1.23%), Cipla (-0.83%), Sun Pharmaceutical Industries (-0.45%).The Mutual Fund holding in Concord Biotech was at 4.30% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Concord Biotech was at 7.79% in 31 Mar 2026. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Jun 10, 2026, 12:46 AM UTC

  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.00
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.63
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    18.65
    Indicates overvaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    -
Price range
Day Range
Lowest
1,192.35
Highest
1,281.00
52 week range
Lowest
987.05
Highest
2,149.90
Concord Biotech Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Torrent Pharmaceuticals
Bullish
4,466.301.231,51,490.3167.3217.10.8317.62
Cipla
Neutral
1,376.75-0.831,11,145.8922.953.870.870.81
Sun Pharmaceutical Industries
Neutral
1,780.50-0.454,27,406.5936.245.770.920.50
Divi's Laboratories
Bullish
6,758.003.711,79,275.7478.6111.520.460.01
Dr Reddy's Laboratories
Neutral
1,268.75-0.551,05,954.4418.633.140.632.34
Mutual Fund Ownership
View all
DSP Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 85.64
  • % of AUM 2.89
LIC MF Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 2.16
  • % of AUM 2.56
Baroda BNP Paribas Innovation Fund Regular Growth
NA
  • Amount Invested (Cr.) 21.42
  • % of AUM 2.15
Baroda BNP Paribas Large and Mid Cap Fund Regular Growth
3/5
  • Amount Invested (Cr.) 31.48
  • % of AUM 1.99
SBI Healthcare Opportunities Fund Regular Growth
NA
  • Amount Invested (Cr.) 69.94
  • % of AUM 1.90
Concord Biotech Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-05-29Audited Results & Final Dividend
2026-02-11Quarterly Results
2025-11-13Quarterly Results
2025-08-08Quarterly Results
2025-05-29Audited Results & Final Dividend
About the company Concord Biotech
  • IndustryBiotechnology & Drugs
  • ISININE338H01029
  • BSE Code543960
  • NSE CodeCONCORDBIO
Concord Biotech Limited is an India-based research and development-driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. Its business verticals include active pharmaceutical ingredients (API), finished formulations, and contract development and manufacturing services. It manufactures API through fermentation and semi-synthetic processes and finished formulations. The Company’s offerings span both biopharmaceutical APIs and formulations across therapeutic areas like immunosuppressants, oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in antibacterial, antifungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, and Teicoplanin. Its API products under development include Daptomycin, Idarubicin, and Pirarubicin.
  • Management Info
  • Sudhir VaidExecutive Chairman of the Board, Managing Director
  • Ankur VaidChief Executive Officer, Joint Managing Director, Executive Director
  • Raviraj KariaChief Financial Officer
  • Hina PatelCompany Secretary and Compliance Officer
  • Devang BhattVice President - Sales and Marketing, Head - Limbasi Plant - 3
  • Manoj KumarVice-President - Formulation Division and Head - Valthera Unit - 2
  • Sundeep BenganiGeneral Manager - International Business Development, Formulation Division
Concord Biotech Share Price FAQs

Concord Biotech is trading at 1271.55 as on Tue Jun 09 2026 10:29:46. This is 6.18% upper as compared to its previous closing price of 1197.50.

The market capitalization of Concord Biotech is 13289.16 Cr as on Tue Jun 09 2026 10:29:46.

The average broker rating on Concord Biotech is Buy. The breakup of analyst rating is given below -

  • 1 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 2 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Concord Biotech is 2149.90 whereas the 52 wk low is 987.05

Concord Biotech can be analyzed on the following key metrics -

  • TTM P/E: 41.13
  • Sector P/E: 27.34
  • Dividend Yield: 0.63%
  • D/E ratio: 0.00

Concord Biotech reported a net profit of 260.91 Cr in 2026.

The Mutual Fund Shareholding was 4.30% at the end of 31 Mar 2026.